2 results
Approved WMORecruiting
The objective of this prospective, observational study is to ensure the safety and the wellbeing of subjects treated with the NEVO* SES.
Approved WMORecruiting
To evaluate the efficacy and safety of tucatinib in combination with trastuzumab and mFOLFOX6 in comparison to mFOLFOX6 given with or without either bevacizumab or cetuximab as first-line (1L) treatment in adults with HER2 positive (HER2+)…